Director
DIN: 01908672
Gaddipati Sankar Basava is currently associated with 2 companies as Director. They serve as a Director at PELLETS PHARMA (INDIA) PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 01908672.Gaddipati Sankar Basava has previously been associated with 1 company in roles such as Whole-time director and Director.Gaddipati Sankar Basava is currently involved in 1 different role. Their most recent position is with PELLETS PHARMA LIMITED as a Director. The first company Gaddipati Sankar Basava was appointed to as a director was PELLETS PHARMA (INDIA) PRIVATE LIMITED. Gaddipati Sankar Basava is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Gaddipati Sankar Basava is currently associated with 2 companies as Director. They serve as a Director at PELLETS PHARMA (INDIA) PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 01908672.Gaddipati Sankar Basava has previously been associated with 1 company in roles such as Whole-time director and Director.Gaddipati Sankar Basava is currently involved in 1 different role. Their most recent position is with PELLETS PHARMA LIMITED as a Director. The first company Gaddipati Sankar Basava was appointed to as a director was PELLETS PHARMA (INDIA) PRIVATE LIMITED. Gaddipati Sankar Basava is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
2
Male
India
Call +91 81049 46419 and we'll pull the verified contact details for you.
Current Companies (2)
Current LLPs (0)
Past Companies (1)
4y 4m 2y 2m Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| PELLETS PHARMA (INDIA) PRIVATE LIMITED | Director | 24-May-2010 |
| PELLETS PHARMA LIMITED | Director | 15-Mar-2022 |